Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

LianBio to Shut Down Operations; Will Distribute $528 Million to Shareholders

publication date: Feb 14, 2024

LianBio, a Princeton-Shanghai biotech, has decided to call it quits. The company said its best option for the future is to close all its operations. Founded four years ago, LianBio emerged from Perceptive Advisors, a New York City company that invested in biopharmas and has $9.5 billion in assets under management. Perceptive, which wanted to participate in China’s drug development scene, formed LianBio to in-license drugs, mainly from its portfolio companies, and bring them to China/Asia. LianBio plans to stop all its operations by the end of 2024 and will distribute a $4.80 dividend/share ($528 million) to its shareholders. More details....

Stock Symbol: (NSDQ: LIAN)

Share this with colleagues: